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IMPORTANCE Breast milk substitutes (BMS) are important nutritional products evaluated in
clinical trials. Concerns have been raised about the risk of bias in BMS trials, the reliability of
claims that arise from such trials, and the potential for BMS trials to undermine breastfeeding
in trial participants. Existing clinical trial guidance does not fully address issues specific to
BMS trials.
OBJECTIVES To establish new methodological criteria to guide the design, conduct, analysis,
and reporting of BMS trials and to support clinical trialists designing and undertaking BMS
trials, editors and peer reviewers assessing trial reports for publication, and regulators
evaluating the safety, nutritional adequacy, and efficacy of BMS products.
DESIGN, SETTING, AND PARTICIPANTS A modified Delphi method was conducted, involving 3
rounds of anonymous questionnaires and a face-to-face consensus meeting between January
1 and October 24, 2018. Participants were 23 experts in BMS trials, BMS regulation, trial
methods, breastfeeding support, infant feeding research, and medical publishing, and were
affiliated with institutions across Europe, North America, and Australasia. Guidance
development was supported by an industry consultation, analysis of methodological issues in
a sample of published BMS trials, and consultations with BMS trial participants and a research
ethics committee.
RESULTS An initial 73 criteria, derived from the literature, were sent to the experts. The final
consensus guidance contains 54 essential criteria and 4 recommended criteria. An 18-point
checklist summarizes the criteria that are specific to BMS trials. Key themes emphasized in
the guidance are research integrity and transparency of reporting, supporting breastfeeding
in trial participants, accurate description of trial interventions, and use of valid and
meaningful outcome measures.
CONCLUSIONS AND RELEVANCE Implementation of this guidance should enhance the quality
and validity of BMS trials, protect BMS trial participants, and better inform the infant nutrition
community about BMS products.
JAMA Pediatr. doi:10.1001/jamapediatrics.2020.0578
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B reast milk substitutes (BMS) are important nutritionalproducts for infants who are not receiving breast milk.Most North American and European infants are ex-
posed to BMS during their first year.1 Infants are sensitive to
health effects of BMS owing to their early stage of develop-
ment when consuming it and their potentially high level of BMS
exposure when BMS are used as a sole source of nutrition. The
potential association of BMS with population health is there-
fore greater than for many other nutritional products, and BMS
need a scientifically robust evidence base so that caregivers
and health care professionals can make informed feeding
choices.2,3 Clinical trials that test BMS safety and evaluate
changes in BMS composition or formulation are the founda-
tion of this evidence base. Several groups have questioned the
methodological quality of published BMS trials and, in turn,
the robustness of their conclusions.4-9 Specific issues identi-
fied include risk of bias related to trial methods, lack of inde-
pendence from BMS manufacturers, and less stringent regu-
latory oversight compared with drug trials.6,10-13 In BMS trials
in which some infants are breastfed at enrollment, trials may
also be failing to support the establishment and maintenance
of breastfeeding in participants.6,14 These concerns, and the
specific issues related to designing BMS trials that answer rel-
evant scientific questions without undermining breastfeed-
ing, suggest a need for new guidance for BMS trials.
We undertook a Delphi consensus to develop new stan-
dards for BMS trials. The new standards aim to support trial-
ists in designing, conducting, analyzing, and reporting trials,
as well as support regulators, critical appraisers, and review-
ers in evaluating BMS trial reports. The guidance relates to in-
tervention trials of BMS in infants enrolled prior to their first
birthday, designed to demonstrate adequate growth and tol-
erance or other objectives. It is designed to complement other
guidance such as that published by the US Food and Drug Ad-
ministration or the European Food Standards Agency, Good
Clinical Practice, or Consolidated Standards of Reporting Trials
(CONSORT). Further details are summarized in the eAppen-
dix in the Supplement.
Methods
A 3-step Delphi consensus process was used to derive new
methodological guidance for BMS trials. This Delphi consen-
sus was undertaken between January 1 and September 30,
2018, with a consensus meeting on October 24, 2018. This
method enables aggregation of the anonymous and indepen-
dent opinions of an expert panel to reach consensus on agreed
criteria.15,16 It is a systematic process of sequential rounds used
to resolve clinical problems for which evidence is limited and
the opinion of stakeholders is important but might be
conflicting.17,18 We invited experts in BMS trials designed to
demonstrate adequate growth and tolerance, BMS trials with
other objectives such as supporting health and nutrition claims,
BMS regulation, trial methods, breastfeeding support, infant
feeding research, and medical publishing. Experts were iden-
tified through literature review and consultation with others
working in these fields. Initial criteria were developed through
review of existing clinical trial and BMS guidance, regulatory
standards, and critical appraisals. We conducted 3 rounds of
email questionnaires to generate, score, and refine criteria
(Figure) and used published requirements for consensus19
(Table 1).20 The UK Health Research Authority was consulted
and confirmed that this study did not require approval by a re-
search ethics committee because it was not considered to be
research on patients. Informed consent was obtained by email
from all study participants. The protocols for this Delphi pro-
cess and an associated systematic review are registered on
PROSPERO (CRD42018091928).21 See the eAppendix in the
Supplement for further details.
Each round of the Delphi survey was piloted by the study
team prior to initiation, and experts were given 3 to 4 weeks
to complete each round, with regular prompts to maximize par-
ticipation. The study team (K.J., B.H., and R.J.B.) was not part
of the Delphi process and did not vote on the criteria.
Delphi Round 1
Experts were asked to rate the importance of criteria that
formed the initial guidance, using the GRADE (Grading of Rec-
ommendations, Assessment, Development and Evaluations)
scale: a score of 1 to 3 corresponds to “not important,” 4 to 6
to “important but not critical,” and 7 to 9 to “critical.”20 If ex-
perts thought they could not comment on a criterion, they se-
lected “unable to score.” Experts were also invited to provide
free text comments, suggest adjustments to the wording of cri-
teria, or suggest new criteria, and to comment on the scope of
the guidance. The study team (K.J. and R.J.B.) summarized
scores, anonymized comments, and classified criteria as es-
sential, recommended, consensus out, or no consensus, as de-
scribed in Table 1.20 All criteria other than consensus out were
carried forward to round 2, together with proposed new cri-
teria, proposed edits to existing wording, and any proposed
merging or splitting of criteria. All changes or new criteria were
highlighted in round 2, together with the anonymous com-
ments from round 1.
Delphi Round 2
Experts were asked to rate the importance of the revised crite-
ria. For criteria repeated from round 1, experts were shown the
consensus outcome and their own scoring. Experts were asked
Key Points
Question What is the best way to ensure the validity of clinical
trials of breast milk substitutes while protecting trial participants?
Findings Through a Delphi consensus project, guidance was
developed to address issues specific to trials of breast milk
substitutes assessing growth and tolerance, as well as trials of
breast milk substitutes with other objectives. This consensus
guidance summarizes best practice for the design, conduct,
analysis, and reporting of trials of breast milk substitutes.
Meaning Use of this guidance, in conjunction with existing clinical
trial regulations, should enhance the quality and validity of trials of
breast milk substitutes, protect trial participants, and support the
evidence base for infant nutrition recommendations.
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to reevaluate the criteria in light of the consensus outcome and
propose further edits or comments, but could not add new cri-
teria at this stage. Responses were classified and criteria modi-
fied in the same way as for round 1, but criteria that were still clas-
sified as no consensus were removed after round 2.
Pilot Systematic Review
A pilot systematic review of a sample of recent BMS trials was
undertaken by the study team (K.J., B.H., and R.J.B.) to evalu-
ate adherence to the preliminary criteria generated in round
2. The findings were summarized for experts before round 3.
Industry Consultation
Revised guidance after round 2 was sent to BMS industry repre-
sentatives for comment on the feasibility and relevance of the
proposed criteria. Breast milk substitute industry representatives
were not invited to score criteria, but their feedback was collated
and added to the guidance document to review in round 3.
Delphi Round 3
Experts were asked to review the revised criteria arising from
round 2, together with the findings of the systematic review
and anonymized industry feedback. Experts were given an op-
portunity to suggest removal, merging, splitting, or changes
to criteria or their ratings. Through analysis of round 3 re-
sponses, essential and recommended consensus criteria were
finalized. Criteria for which the response to industry com-
ments was unresolved or conflicting comments were re-
ceived during round 3 were highlighted for discussion during
the consensus meeting.
Consensus Meeting
Experts were invited to attend the final consensus meeting in
person or by web link. The meeting focused on criteria for
which consensus had not yet been achieved. Each relevant cri-
terion was discussed until agreement was reached to retain,
edit, or remove it from the guidance. The meeting was facili-
tated by an independent nonvoting chair with experience in
BMS regulation, Peter Aggett, MD, PhD (University of Lan-
caster, UK). Experts were given the opportunity to comment
on each criterion, and for those who wished to raise issues
anonymously, opportunities were given to submit questions
or comments prior to or during the meeting, to be raised by
the chair on their behalf. The study team (K.J., B.H., and R.J.B.)
circulated minutes after the consensus meeting, and the meet-
ing was recorded. Any final edits and formatting changes were
agreed on through email exchange after the meeting.
Trial Participant and Ethics Committee Consultation
After the consensus meeting, the final criteria were sent to par-
ents of infants who had participated in a BMS trial and to the
Figure. Summary of Delphi Consensus Process
73 Draft criteria circulated to panelStart:
51 Consensus in, 11 no consensus, 9 consensus out, 25 newEnd:
29 Consensus in, without or with only minor modification
22 Consensus in, with significant modification
11 No consensus
9 Consensus out (6) or merged with another criterion (3)
25 New criteria (21) or split into 2 criteria (2)
Pilot systematic review
Selective outcome reporting
identified as a potential issue 
Industry consultation 
General comments received, and specific
suggestions for 42 of the 69 criteria 
Round 1
87 Revised criteria circulated to panelStart:
69 Consensus in (64 essential, 5 recommended) 18 removedEnd:
60 Consensus in, without or with only minor modification
9 Consensus in, with significant modification
9 No consensus (removed)
9 Consensus out (1) or merged with other criteria (8)
0 Split into 2 criteria
Round 2
69 Revised criteria circulated to panel Start:
64 Essential, 5 recommended, none consensus outEnd:
• Number of criteria or level of recommendation did not change
• Modifications suggested to several criteria
• 19 Criteria highlighted for discussion at consensus meeting 
Consensus meeting  
• Discussed 19 criteria with unresolved issues relating to industry feedback
or round 3 comments, and reviewed scope of guidance and key definitions 
• 1 Criterion removed, 4 merged with existing criteria during meeting,
6 subsequent to meeting, 16 modified during meeting 
• Key issues discussed were: (1) transparency of trial conduct, reporting,
and adverse event coding; (2) study design and implications for
breastfeeding; (3) description of experimental and control BMS; and
(4) study end points
• All revised criteria reached consensus
Final guidance document
54 Essential and 4 recommended criteria
BMS trial checklist
18 Criteria specific to BMS trials
Round 3
A summary of the actions taken during each step of the Delphi consensus
process is shown. BMS indicates breast milk substitute.
Table 1. Definition of Consensus for the Delphi Process
Consensus
classificationa Description Definition
Essential Consensus that the criterion is
essential to the design or
conduct of BMS trials
≥70% Of experts
scoring as 7-9
and <15% of
experts
scoring as 1-3
Recommended Consensus that the criterion is
recommended with regard to
the design or conduct of BMS trials
≥70% Of experts
scoring as 4-6
and <15% of
experts
scoring as 1-3
Out Consensus that the criterion
should not be included in
the core methodological criteria
≥70% Of experts
scoring as 1-3
and <15% of
experts
scoring as 7-9
No consensus Uncertainty about importance
of the criterion
Anything else
Abbreviations: BMS, breast milk substitute; GRADE, Grading of
Recommendations, Assessment, Development and Evaluations.
a Consensus classification used the GRADE method. A score of 1 to 3
corresponds to not important, a score of 4 to 6 to corresponds to important
but not critical, and a score of 7 to 9 corresponds to critical.20
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London Riverside National Health Service Research Ethics
Committee for formal comment.
Results
Setting and Participants
This Delphi consensus was undertaken between January 1 and
September 30, 2018, with a consensus meeting on October 24,
2018. Twenty-eight experts were contacted and 23 partici-
pated in at least 1 stage of the Delphi survey: 6 clinical trial-
ists, 9 experts in BMS regulation, 5 clinical trial methodolo-
gists, 2 experts in breastfeeding support and infant feeding
research, and 1 medical journal editor. Experts were affiliated
with institutions in Europe, North America, and Australasia.
Sixteen of the experts were able to contribute to the final con-
sensus meeting. Six of 7 invited BMS industry representa-
tives provided comments between June 1 and September 30,
2018, comprising representatives from Danone Nutricia, Nestlé
Nutrition, Abbott Nutrition, Hipp, Friesland Campina, and
Dairy Goat Co-operative.
Delphi Survey Results
Initial guidance for round 1 included 73 criteria derived from
clinical trials, BMS and breastfeeding guidance, and apprais-
als of the BMS trial literature. General comments raised in the
BMS industry consultation related to overlap with existing clini-
cal trial guidance, the value of study designs other than ran-
domized clinical trials, definitions of BMS and other nutri-
tional products, and the title and scope of the guidance.
Preliminary findings from the pilot phase of the systematic re-
view, which evaluated a sample of 61 recent BMS trials, were
a lack of independently funded studies and a high prevalence
of nonregistered trial outcomes highlighted in publication
abstracts.
The outcomes at each stage of the Delphi process are sum-
marized in the Figure. The final guidance comprises 54 essen-
tial criteria (eTable 1 in the Supplement) and 4 recommended
criteria (eTable 2 in the Supplement). Of these, 18 criteria are
specific to BMS trials, which are summarized as a checklist in
Table 2.20,22 The 58 criteria are elaborated in the eAppendix
in the Supplement, including a list of definitions for the key
terms used. Key issues discussed at the consensus meeting cen-
tered around 4 themes.
Theme 1: Research Integrity and Reporting Transparency
Experts stressed the importance of transparency of trial con-
duct and reporting: that all BMS trials are registered; that trial
outcomes are made publicly available, in line with current ini-
tiatives in medical research that aim to increase access to origi-
nal data sets23-25; and that oversight of trial conduct,
analysis, and reporting, including adverse event coding, is in-
dependent. Independence was conceptualized as usually
meaning that trial oversight was the responsibility of the prin-
cipal investigator, and should not be the responsibility of an
employee of the BMS industry or any other entity with a po-
tential financial interest in the outcome of the trial. It was
thought that in-house industry-led statistical planning and
analysis is not appropriate unless there is complete transpar-
ency owing to audit by regulators or full publication of par-
ticipant-level outcome data, such that all statistical analyses
can be independently verified. When blinded BMS products
are used as trial interventions, industry collaboration may be
necessary, but trialists and BMS manufacturers should avoid
creating financial dependencies and avoid industry control of
trial conduct, analysis, or reporting. The TRIGR (Trial to Re-
duce Insulin-Dependent Diabetes Mellitus in the Genetically
at Risk) study was cited as a good example of “arm’s length”
BMS trial practice, in which the BMS manufacturer’s role was
limited to provision of trial interventions.26 Experts also em-
phasized that significant trial amendments—especially changes
to participant inclusion criteria, experimental or control treat-
ment, and methods, timing, or nature of outcome measures—
should be recorded by way of an update to the BMS trial’s rec-
ord on a World Health Organization–approved clinical trial
registry.
Theme 2: Study Design and Breastfeeding Support
The provision of breastfeeding support in BMS trials was a con-
troversial area, resolved by experts through identifying the im-
portance of distinguishing 2 different approaches to breast-
feeding support for 2 different types of studies. In BMS trials
designed to meet a noninferiority or equivalence objective—
typically those aiming to demonstrate adequate infant growth
and tolerance of a new BMS product—experts thought that par-
ticipating infants should be fully BMS fed and the decision not
to use breast milk should be firmly established prior to enroll-
ment in the trial. After randomization, additional breastfeed-
ing support is not usually required for participants in these
studies, but it is important to ensure that appropriate breast-
feeding support has been provided prior to enrollment. In some
countries, regulators have additional specific requirements for
infant growth and tolerance trials—for example, in the United
States, growth trials must enroll infants at age 14 days or
younger with an intervention period that lasts for 15 weeks or
more.27 These noninferiority or equivalence trials should usu-
ally be analyzed using both intention-to-treat and a prespeci-
fied per-protocol data set.
In a separate group of BMS trials, usually pragmatic supe-
riority trials aiming to generate data to support a nutrition or
health claim, some infants are receiving breast milk at enroll-
ment. Superiority trials should usually be analyzed using an
intention-to-treat data set. In trials in which some infants are
receiving breast milk at enrollment, experts agreed that it is
important to demonstrate adequate support for breast milk
feeding within the trial. In these studies, it was thought that
an international board–certified lactation consultant em-
ployed by an academic or health care institution would be best
placed to offer skilled breast milk feeding support.
Theme 3: Description of Trial Interventions
Experts confirmed the scope of this guidance as being BMS,
as defined by the World Health Organization, including all in-
gredient additives to BMS that are delivered to an infant within
a BMS. Experts agreed that composition and formulation of the
experimental and control BMS need to be fully described and
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related to existing marketed products, and that the timing of
the intervention period should be appropriate for the trial ob-
jectives. Trial participants’ intake of both experimental and
control BMS and any other foods should be accurately re-
corded.
Theme 4: Study Outcomes
Experts agreed that primary and secondary study outcomes
should be clearly established a priori and that statistical power
calculations for the primary outcome should be based on a clini-
cally meaningful effect size. The end points used to measure
Table 2. Abbreviated Checklist of Criteria Specific for Clinical Trials of BMS
Domain, item No.a Consensus statement
BMS composition and
formulation
4a The trial protocol and trial reports clearly describe the composition and formulation
of the experimental and control BMS and their relationship, if any, to existing BMS
products marketed anywhere in the world
4b The experimental and control BMS both meet legally required compositional standards,
and any instructions for safe reconstitution of BMS by trial participants are consistent
with relevant national or international guidance
4c The trial protocol and trial reports clearly describe any differences between
experimental and control BMS which are additional to the constituent(s) of interest
and consider their potential impact on the trial results
4d Appropriate preclinical studies have been performed for previously untested
components of BMS
Intervention
7a For trials with a primary noninferiority or equivalence objective, such as growth and
tolerance trials, participants should be exclusively BMS fed at enrollment
7b The trial protocol and trial reports describe how intake of experimental and control
BMS is recorded during the trial, and the trial reports summarize experimental and
control BMS intake in each treatment group during the intervention period
7c Trial participants’ intake of any foods other than experimental and control BMS
during the intervention and data collection periods is recorded
7d The age of infants at the start and end of the intervention period is appropriate
for the trial objectives, and the age range at enrollment is sufficiently narrow
for treatment effects to be comparable across the trial population
Outcome assessment
8c For growth outcomes, trial reports should comment on whether metabolic and
developmental outcomes were also evaluated
Analysis
12b Statistical analyses which were not prespecified in the trial protocol are interpreted
with caution and are not used as the basis for claims in the trial conclusions, or to
support recommendations for infant feeding
Ethics for trials
in BMS-fed infants
14 For trials where participants are all exclusively BMS fed at enrollment, such as
growth and tolerance trials, carers’ decision not to breastfeed should be firmly
established prior to enrollment in the trial
Ethics for trials
where some
participants
consume breast milkb
15a The ethics statement in the trial protocol and trial reports clearly states how
breastfeeding was supported during the trial
15b Trial methods do not involve anything that may be interpreted as an incentive to
introduce BMS to an infant’s diet and emphasize the superiority of breastfeeding
over BMS in all literature
15c Randomization and treatment allocation do not occur until the time point when a
participant expresses an intention to introduce BMS, and participants are offered
skilled breastfeeding support from a trained breastfeeding counselor at this stage,
prior to randomization and introduction of experimental and control BMS
15d Incentives to participate in the trial do not include provision of free or discounted
BMS, samples, equipment, or other gifts related to BMS and its marketing; if free or
discounted BMS is felt to be essential, then a similar level of reimbursement should be
provided for continued breast milk feedingc
15e For trials which involve groups of infants at increased risk of a severe adverse event
related to BMS use, a high level of scrutiny regarding the possibility of a negative
impact on breast milk feeding is requiredc
Limitations
19c Trial reports discuss the limitations of any findings which are based on analysis of
participants with a minimum level of experimental or control BMS intakec
Conflict of interests
20d An investigator who is independent of the BMS industry takes overall responsibility
for the conduct of the trial, planning and conduct of statistical analyses, decision to
publish, reporting, and interpretation of the trial findings, and ensures that the
planning and conduct of statistical analyses are led independently of the BMS industry
Abbreviations: BMS, breast milk
substitute; GRADE, Grading of
Recommendations, Assessment,
Development and Evaluations.
a Item No. refers to the full criteria in
eTables 1 and 2 in the Supplement.
Criteria were scored using the
GRADE scale.20
b For growth and tolerance trials, or
other trials with noninferiority or
equivalence objectives, participants
should be fully BMS fed and the
decision not to breastfeed should
be firmly established prior to
enrollment in the trial. For other
trials, where some participants may
be receiving breast milk at
enrollment or during the
intervention period, trial design and
conduct should comply with the
International Code of Marketing of
Breast-milk Substitutes22 and
subsequent relevant World Health
Assembly resolutions to avoid
undermining breast milk feeding.
c Recommended criteria. All other
criteria were classified as essential
(Table 1).
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each outcome should be valid and clinically relevant, and the
use of surrogate end points in place of clinical end points should
be appropriately justified and interpreted.
Trial Participant Viewpoints
After the consensus meeting, 16 BMS trial participants were
contacted and 5 responded, with 3 providing detailed com-
mentary and telephone discussion regarding the criteria. All
responding BMS trial participants were supportive of the fi-
nal criteria, especially independence of trial conduct and analy-
sis and transparent reporting of outcomes. The BMS trial par-
ticipants commented in detail on 2 criteria concerning the
subset of BMS trials in which some infants are receiving breast
milk at enrollment. These criteria (15c and 15d) are not rel-
evant to trials in which infants are exclusively fed BMS prior
to enrollment and the parents’ decision to not provide breast
milk is firmly established prior to enrollment. In support of cri-
terion 15c, they thought that provision of trial BMS should not
occur until randomization, and that this provision should not
occur during pregnancy or (where relevant) during exclusive
breast milk feeding, to avoid providing an incentive to use BMS
in place of breast milk. However, participants thought that once
a parent decides to supplement breast milk feeding with a BMS,
the use of other BMS products should be permitted prior to pro-
vision of trial BMS, to avoid feeding problems while awaiting
delivery of the experimental or control BMS. In relation to cri-
terion 15d, BMS trial participants viewed the provision of free
trial BMS as useful, and supportive for participants with fi-
nancial constraints, but recognized that this provision may in-
centivize breastfeeding women to use BMS in place of breast
milk. One participant suggested that if free BMS is provided
in a trial that includes breastfed infants, a financial incentive
to continue breastfeeding could also be provided. The ex-
perts agreed by email to add this suggestion to criterion 15d.
Discussion
Clinical trials of BMS require specific guidance to ensure that
they are methodologically sound, such that their results may
reliably inform caregivers and health care professionals. This
Delphi survey has derived, through expert consensus, a stan-
dard consisting of 58 criteria to support the design, conduct,
analysis, transparent reporting, and evaluation of BMS trials.
Implementation of this standard, in conjunction with exist-
ing methodological and ethical guidance, could better pro-
tect BMS trial participants and ultimately improve the qual-
ity of BMS products and information associated with them for
consumers.
The validity of this Delphi process is supported by the ex-
tensive review of relevant sources that informed the initial cri-
teria and the engagement of a comprehensive panel of ex-
perts who provided a diverse range of experience and insight.
The consistent and anonymous application of each iteration,
as defined a priori in the protocol, minimized bias and ma-
nipulation of experts’ opinions. Outcomes from analysis of a
sample of BMS trials identified by a pilot systematic review use-
fully informed the Delphi process. The inclusion of a face-to-
face consensus meeting resolved any remaining issues. It was
not possible to maintain anonymity of experts at this stage, but
the meeting was carefully moderated by an independent chair,
through whom experts were invited to submit questions or is-
sues anonymously. Although only 13 of 23 Delphi experts at-
tended the meeting, 3 others provided written comments that
were considered during the meeting; a full summary of the dis-
cussions and decisions, and then the final manuscript, were
shared with all experts for comment and approval after the
meeting. One expert withdrew from authorship of the article
because of disagreement with specific criteria, although these
met the predefined requirements for consensus summarized
in Table 1.20 To limit bias introduced during development of
the criteria, the study team reproduced all experts’
comments anonymously and verbatim in each round. Indus-
try representatives were asked to comment, but not to score
the criteria.
Limitations
This study had some limitations. We had good representa-
tion from Europe and North America, where most BMS trials
are conducted, but less good representation from other re-
gions where BMS trials are less commonly conducted. We did
not involve industry in the whole Delphi process, because that
would represent a conflict of interest for some experts in re-
lation to their regulatory work. This new guidance therefore
represents the views of trialists, methodologists, lactation con-
sultants, infant feeding researchers, regulators, and a journal
editor rather than the views of industry representatives. Par-
ents of infants who had participated in a BMS trial com-
mented on the criteria at the final stage but were not mem-
bers of the Delphi panel and did not score criteria.
Conclusions
We have developed new, consensus-based guidance for the de-
sign, conduct, analysis, and reporting of BMS trials. To achieve
our aim of improving the conduct and reporting of BMS trials,
this guidance must come to represent the expected standard
in this field. Industry representatives, regulators, and clinical
trialists have been able to contribute their views on the feasi-
bility and practicality of these criteria, and some regulators such
as Health Canada have already incorporated the criteria into
their guidance.28 If BMS trialists incorporate this guidance in
their clinical trials, in conjunction with existing methodologi-
cal and ethical guidance, the quality and validity of their trials
will benefit, so participants will be protected and the infant
nutrition communitywill be better informed about the safety
and potential efficacy of BMS products.
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